HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Pharmaceutical Industries Ltd.

www.tevapharm.com

Latest From Teva Pharmaceutical Industries Ltd.

Duo Dance Two-Step To Cut Irish Truvada Term

Both steps of a test laid down by the Court of Justice for the European Union for invalidating supplementary protection certificates for combination products were satisfied by Mylan and Teva in an Irish dispute over protection for Gilead’s Truvada combination antiretroviral.

Intellectual Property Ireland

Teva Seeks Global Resolution Of Opioid Litigation

Teva and three distributors settle with two plaintiffs; PBMs are defendants in next case as Teva also reaches an agreement in principal with four attorneys general for global settlement framework.

Legal Issues Strategy

Teva Seeks Global Resolution Of Opioid Litigation As Bellwether Trial Is Halted

Teva and three distributors settle with two plaintiffs; PBMs are defendants in next case as Teva also reaches an agreement in principal with four attorneys general for global settlement framework. 

Legal Issues Advertising, Marketing & Sales

Teva Defends Vincristine Discontinuation Decision

Amid emotive US mainstream media coverage of shortages of the children’s cancer treatment vincristine, Teva insists it is not to blame after discontinuing production of the chemotherapy agent.

Cancer Manufacturing
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register